Search Results
Feb 17, 2026, 10:55 ET Database Management System (DBMS) Market Driven by Cloud Adoption, Big Data Analytics, and Rising Enterprise Digital Transformation at a CAGR of 5.5% : - Market Research Intellect
Therapeutics), Type II (Biologics and Monoclonal Antibodies), Type III (Cell and Gene Therapies), Type IV (Vaccines and Immune Modulators), Type V (RNA‑Based Therapeutics)), By Application (Oncology Treatment Channels, Rare Disease Therapeutics, Cell and Gene Therapy Platforms, Respiratory and Immunology
More news about: Market Research Intellect
Feb 17, 2026, 10:40 ET Financial Wellness Benefits Market Poised for Robust Expansion Amid Rising Employer Focus on Workforce Well-Being and Digital Financial Planning Solutions - Market Research Intellect
Therapeutics), Type II (Biologics and Monoclonal Antibodies), Type III (Cell and Gene Therapies), Type IV (Vaccines and Immune Modulators), Type V (RNA‑Based Therapeutics)), By Application (Oncology Treatment Channels, Rare Disease Therapeutics, Cell and Gene Therapy Platforms, Respiratory and Immunology
More news about: Market Research Intellect
Feb 17, 2026, 09:00 ET Diakonos Oncology Announces Study to Continue after First DSMB Safety Review of DOC1021 in Phase 2 GBM Study
approach, which mimics a viral infection, unlocks a synergistic and exponentially more powerful tumor killing TH1 response driven by dual protein and RNA antigen sourcing, and it allows targeting of the complete cancer antigen pool. Moreover, the approach does not require any molecular modification of
More news about: Diakonos Oncology
Feb 16, 2026, 09:00 ET Data Presented at SABCS 2025 Demonstrated that the Endocrine Activity Index® (EAI®) May Identify Patients Most Likely to Benefit from Extended Endocrine Therapy
measures endocrine activity in a breast tumor and for prognostic use, the Index Score is adjusted for baseline prognosis using molecular subtype genes (RNA4) and clinical factors such as tumor size and regional lymph node involvement. The EAI test has been shown in various studies to be a consistent prognostic
More news about: Delphi Diagnostics Inc
Feb 13, 2026, 11:00 ET Open Pontoon Boat Market Poised for Steady Expansion from USD 1.5 Billion in 2024 to USD 2.3 Billion by 2033, Supported by Rising Recreational Boating Demand : - Market Research Intellect
Therapeutics), Type II (Biologics and Monoclonal Antibodies), Type III (Cell and Gene Therapies), Type IV (Vaccines and Immune Modulators), Type V (RNA‑Based Therapeutics)), By Application (Oncology Treatment Channels, Rare Disease Therapeutics, Cell and Gene Therapy Platforms, Respiratory and Immunology
More news about: Market Research Intellect
Feb 13, 2026, 10:39 ET Electronic Discovery Software Market to Reach USD 10.1 Billion by 2033, Fueled by Rising Digital Litigation, Regulatory Compliance Needs, and Advanced Analytics Adoption: Market Research Intellect
Therapeutics), Type II (Biologics and Monoclonal Antibodies), Type III (Cell and Gene Therapies), Type IV (Vaccines and Immune Modulators), Type V (RNA‑Based Therapeutics)), By Application (Oncology Treatment Channels, Rare Disease Therapeutics, Cell and Gene Therapy Platforms, Respiratory and Immunology
More news about: Market Research Intellect
Feb 13, 2026, 09:12 ET Soin Neuroscience and Lilac Biosciences Launch Collaboration to Study RNA Signatures in Pain and Neuromodulation
biotechnology company spun out of the Giuliani RNA Center at Brown University, developing RNA-based analytical tools to enable discovery and translational research.Lilac focuses on quantitative RNA workflows designed to enable reproducible measurement of RNA biology across a range of research applications,
More news about: Soin Neuroscience
Feb 13, 2026, 07:00 ET Insmed To Present at March 2026 Investor Conferences
early-stage programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue.Headquartered in Bridgewater, New Jersey, Insmed has offices and research locations throughout the United States,
More news about: Insmed Incorporated
Feb 13, 2026, 06:02 ET 13 Press Releases You Need to See This Week
Lilly to acquire Orna Therapeutics to advance cell therapiesOrna is advancing a new class of therapeutics utilizing engineered circular RNA paired with novel lipid nanoparticles to allow the patient's own body to generate cell therapies that can treat underlying disease. Under the terms of
More news about: PR Newswire
Feb 12, 2026, 22:20 ET Omics Empower 香港實驗室正式推出 Xenium™ 原位空間轉錄組服務
年 7 月香港實驗室啟用以來，Omics Empower 持續在港提供本地化的單細胞測序與空間轉錄組服務，並可接收新鮮組織與細胞樣本進行單細胞測序。本地送樣與在地處理模式有助於縮短樣本處理週期，降低 RNA 降解風險並維持細胞活力，從而支持高品質單細胞數據的生成，同時提升專案溝通與執行效率。Xenium™ 由 10x Genomics 開發，可在保留組織空間結構的前提下，對 RNA 分子進行原位定位與定量分析，實現單細胞及亞細胞層級解析度。該技術廣泛應用於腫瘤微環境研究、神經科學、免疫學及轉譯醫學等領域，有助於研究人員解析細胞在原位環境中的分子特徵與空間組織關係。據公開資料顯示，Omics
More news about: Omics Empower
Feb 12, 2026, 05:47 ET Ribo und Ribocure geben exklusive globale Lizenzvereinbarung mit Madrigal für neuartige siRNA-Therapeutika gegen MASH bekannt
mit Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) („Madrigal") eine exklusive weltweite Lizenzvereinbarung für sechs präklinische Small-Interfering-RNA (siRNA)-Programme zur Behandlung von metabolischer Dysfunktion-assoziierter Steatohepatitis (MASH) abgeschlossen haben.
More news about: Suzhou Ribo Life Science Co., Ltd.
Feb 11, 2026, 06:49 ET Ribo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASH
into an exclusive worldwide licensing agreement with Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) ("Madrigal") for six pre-clinical small interfering RNA (siRNA) programs for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).
More news about: Suzhou Ribo Life Science Co., Ltd.
Feb 11, 2026, 06:25 ET Ribo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASH
into an exclusive worldwide licensing agreement with Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) ("Madrigal") for six pre-clinical small interfering RNA (siRNA) programs for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).
More news about: Suzhou Ribo Life Science Co., Ltd.
Feb 10, 2026, 11:25 ET The Mark Foundation and The Sontag Foundation Lead Coalition to Propel Novel Brain Tumor Therapy Research with $4 Million in New Grants
ASPIRE Awards — $250,000 each for one-year projectsAntisense Oligonucleotides (ASOs) Targeting the Long Noncoding RNA as Novel Immunotherapeutic Agents in Glioblastoma E. Antonio Chiocca, MD, PhD, Brigham and Women's HospitalTargeting
More news about: The Mark Foundation for Cancer Research
Feb 10, 2026, 09:05 ET Helix Partners with Mawi DNA Technologies to Expand Access to Non-Invasive Genomic Sample Collection
collection product on the market proven to produce a high quality DNA sample with low bacterial DNA content. Mawi also supplies products for collection of RNA, microbiome, intact cells, and whole blood. At Mawi, The Future of Biosampling is Here™. For more information, visit
More news about: Helix
Feb 10, 2026, 09:00 ET Circular Genomics Finalizes Exclusive IP Licenses with Leading Global Research Institutions to Advance circRNA Blood Test for Alzheimer's Disease
DIEGO, Feb. 10, 2026 /PRNewswire/ -- Circular Genomics, a molecular diagnostics company pioneering circular RNA (circRNA)–based biomarkers for neurodegenerative disease, today announced the completion of exclusive intellectual property licensing agreements with
More news about: Circular Genomics
Feb 10, 2026, 08:00 ET Vanscoy Rare Pharmacy Selected as Exclusive Distribution Pharmacy for Redemplo® (plozasiran) for adults with Familial Chylomicronemia Syndrome (FCS)
silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that
More news about: Vanscoy Rare Pharmacy
Feb 09, 2026, 09:20 ET NeuroSense Expands Global IP Protection Strategy With Granted Australian Patent Covering PrimeC Composition
target several key mechanisms of ALS and AD, that contribute to neuron degeneration, inflammation, iron accumulation and impaired ribonucleic acid ("RNA") regulation to potentially inhibit the progression of ALS and AD.About ALSAmyotrophic lateral sclerosis ("ALS")
More news about: NeuroSense
Feb 09, 2026, 09:00 ET Co-Diagnostics to Showcase PCR Platform at World Health Expo Labs Dubai
technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory
More news about: Co-Diagnostics
Feb 09, 2026, 08:18 ET EQT Life Sciences co-leads USD 39 million Series A in Aerska to help systematically deliver RNA medicines to the brain
pioneering systemically delivered RNA medicines capable of reaching the brain to treat neurological diseases at their source. The platform uses proprietary "brain shuttle" technology to overcome the blood-brain barrier, a fundamental challenge that has historically limited RNA therapeutics in CNS diseases.
More news about: EQT
Feb 09, 2026, 08:16 ET EQT Life Sciences co-leads USD 39 million Series A in Aerska to help systematically deliver RNA medicines to the brain
pioneering systemically delivered RNA medicines capable of reaching the brain to treat neurological diseases at their source. The platform uses proprietary "brain shuttle" technology to overcome the blood-brain barrier, a fundamental challenge that has historically limited RNA therapeutics in CNS diseases.
More news about: EQT
Feb 09, 2026, 07:00 ET Lilly to acquire Orna Therapeutics to advance cell therapies
cell-driven autoimmune diseases. Experiments to date suggest that Orna's circular RNA platform may deliver more durable expression of therapeutic proteins and therefore unlock treatments that are not feasible with current RNA or cell therapy platforms."Early autologous CAR-T studies have shown the
More news about: Eli Lilly and Company
Feb 06, 2026, 12:09 ET New England Biolabs ® Proudly Partners with Automation Providers to Support NGS Library Prep Automation Globally
optimize and verify performance across a wide range of NEBNext products, including NEBNext UltraExpress® DNA and RNA Library Prep, NEBNext Enzymatic Methyl-seq (EM-seq™), and NEBNext Low-bias Small RNA Kits."Standardized, automation-ready workflows are critical for scaling NGS across organizations and
More news about: New England Biolabs, Inc.
Feb 05, 2026, 12:35 ET Zenocutuzumab‑zbco Receives FDA Orphan Drug Designation for Treatment of Cholangiocarcinoma
rearrangements and typically occur without other oncogenic alterations. Like other fusions, they are best detected with a combination of tissue-based RNA and DNA next generation sequencing.Systemic first-line treatment regimens in cholangiocarcinoma yield modest clinical benefit, with overall response
More news about: Partner Therapeutics, Inc.
Feb 05, 2026, 09:00 ET Co-Diagnostics Joint Venture CoSara Receives CDSCO License to Manufacture and Sell CoSara PCR Pro™ Instrument
technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory
More news about: Co-Diagnostics